1-20 of 33
IA Mayer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract ES6-2: CDK4/6 for ER+

IA Mayer
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): ES6-2.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-ES6-2
Published: 15 February 2022
View article
Journal Articles

Abstract P2-11-01: Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC)

K Kalinsky, SJ Isakoff, SM Tolaney, D Juric, IA Mayer, LT Vahdat, JR Diamond, J O'Shaughnessy, RL Moroose, AD Santin, NC Shah, V Abramson, DM Goldenberg, RM Sharkey, SA Washkowitz, WA Wegener, R Iannone, A Bardia
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P2-11-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P2-11-01
Published: 15 February 2019
View article
Journal Articles

Abstract P5-11-01: Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor antagonist/ degrader (SERD)

JM Spoerke, A Daemen, C-W Chang, J Giltnane, C Metcalfe, MN Dickler, A Bardia, JA Perez Fidalgo, IA Mayer, V Boni, EP Winer, EP Hamilton, M Bellet, A Urruticoechea, A Gonzalez Martin, J Cortes, M Martin, M Gates, S Cheeti, J Fredrickson, X Wang, LS Friedman, L Liu, R Li, IT Chan, L Mueller, S Milan, J Lauchle, EW Humke, MR Lackner
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P5-11-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P5-11-01
Published: 15 February 2019
View article
Journal Articles

Abstract PD3-06: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT trial

LM Smyth, SA Piha-Paul, C Saura, S Loi, J Lu, GI Shapiro, D Juric, IA Mayer, C Arteaga, M de la Fuente, AM Brufksy, M Mau-Sørensen, M Arnedos, V Moreno, J-H Sohn, L Schwartzberg, X Gonzàlez-Farré, A Cervantes, G Mann, S Shahin, RE Cutler, Jr., LD Eli, F Xu, T Bagulho, AS Lalani, R Bryce, DB Solit, DM Hyman, F Meric-Bernstam, J Baselga
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): PD3-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-PD3-06
Published: 15 February 2019
View article
Journal Articles

Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial

D Juric, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, H Iwata, P Conte, IA Mayer, B Kaufman, T Yamashita, Y-S Lu, K Inoue, M Takahashi, Z Pápai, A-S Longin, D Mills, C Wilke, D Sellami, F Andre
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): GS3-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-GS3-08
Published: 15 February 2019
View article
Journal Articles

Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial

K Albain, RJ Gray, JA Sparano, DF Makower, KI Pritchard, DF Hayes, CE Geyer, Jr., EC Dees, MP Goetz, JA Olson, Jr., T Lively, SS Badve, TJ Saphner, LI Wagner, TJ Whelan, MJ Ellis, S Paik, WC Wood, PM Ravdin, MM Keane, HL Gomez, PS Reddy, TF Goggins, IA Mayer, AM Brufsky, DL Toppmeyer, VG Kaklamani, JL Berenberg, J Abrams, GW Sledge, Jr.
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): GS4-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-GS4-07
Published: 15 February 2019
View article
Journal Articles

Abstract PD4-07: Genenomic landscape of breast cancers with FGFR1 amplification and FGFR1/CCND1 co-amplification revealed by targeted capture next generation sequencing

PI Gonzalez-Ericsson, MV Estrada, L Formisano, VM Jansen, IA Mayer, BN Rexer, VG Abramson, M Levy, JM Balko, TP Stricker, CL Arteaga, ME Sanders
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): PD4-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-PD4-07
Published: 15 February 2018
View article
Journal Articles

Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)

MN Dickler, R Villanueva, JA Perez Fidalgo, IA Mayer, V Boni, EP Winer, EP Hamilton, M Bellet, A Urruticoechea, A Gonzalez-Martin, J Cortes, M Martin, J Giltnane, M Gates, S Cheeti, J Fredrickson, X Wang, LS Friedman, JM Spoerke, C Metcalfe, L Liu, R Li, R Morley, U McCurry, IT Chan, L Mueller, S Milan, J Lauchle, EW Humke, A Bardia
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): PD5-10.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-PD5-10
Published: 15 February 2018
View article
Journal Articles

Abstract P1-12-01: Withdrawn

A Bardia, LT Vahdat, JR Diamond, K Kalinsky, J O'Shaughnessy, RL Moroose, SJ Isakoff, SM Tolaney, AD Santin, V Abramson, NC Shah, SV Govindan, P Maliakal, RM Sharkey, WA Wegener, DM Goldenberg, IA Mayer
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P1-12-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P1-12-01
Published: 15 February 2018
View article
Journal Articles

Abstract P5-21-06: Alpelisib plus letrozole in estrogen receptor-Positive (ER+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC): Safety and preliminary efficacy analysis from a phase 1b trial

D Juric, A Gonçalves, E Hamilton, V Boni, IA Mayer, S Turri, Y Wang, FD Vogl, D Sellami, M Campone
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P5-21-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P5-21-06
Published: 15 February 2018
View article
Journal Articles

Abstract P5-21-05: Withdrawn

LM Smyth, M Oliveira, E Ciruelos, K Tamura, A El-Khoueiry, A Mita, B You, DJ Renouf, M-P Sablin, A Lluch, IA Mayer, H Bando, H Yamashita, H Ambrose, E de Bruin, TH Carr, C Corcoran, A Foxley, JPO Lindemann, R Maudsley, M Pass, A Rutkowski, G Schiavon, U Banerji, M Scaltriti, BS Taylor, S Chandarlapaty, J Baselga, DM Hyman
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P5-21-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P5-21-05
Published: 15 February 2018
View article
Journal Articles

Abstract P5-21-32: AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer

LM Smyth, M Oliveira, E Ciruelos, K Tamura, A El-Khoueiry, A Mita, B You, DJ Renouf, M-P Sablin, A Lluch, IA Mayer, H Bando, H Yamashita, H Ambrose, E de Bruin, TH Carr, C Corcoran, A Foxley, JPO Lindemann, R Maudsley, M Pass, A Rutkowski, G Schiavon, U Banerji, M Scaltriti, BS Taylor, S Chandarlapaty, J Baselga, DM Hyman
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P5-21-32.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P5-21-32
Published: 15 February 2018
View article
Journal Articles

Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results

A Bardia, LT Vahdat, J Diamond, K Kalinsky, J O'Shaughnessy, RL Moroose, SJ Isakoff, SM Tolaney, AD Santin, V Abramson, NC Shah, SV Govindan, P Maliakal, RM Sharkey, WA Wegener, DM Goldenberg, IA Mayer
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): GS1-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-GS1-07
Published: 15 February 2018
View article
Journal Articles

Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer

L Formisano, Y Lu, VM Jansen, JA Bauer, A Hanker, P Gonzalez Ericsson, K-M Lee, MJ Nixon, AL Guerrero-Zotano, LJ Schwarz, M Sanders, D Sudhan, TC Dugger, MR Cruz, A Behdad, M Cristofanilli, A Bardia, J O'Shaughnessy, IA Mayer, CL Arteaga
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): GS6-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-GS6-05
Published: 15 February 2018
View article
Journal Articles

Abstract OT3-05-09: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (Maintain trial)

K Kalinsky, PS Mundi, C Chiuzan, MK Accordino, MS Trivedi, JA Sparano, SY Oh, A Tiersten, R O'Regan, FJ Esteva, S Jain, IA Mayer, A Forero, C Vaklavas, L Baer, K Crew, DL Hershman
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): OT3-05-09.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-OT3-05-09
Published: 15 February 2018
View article
Journal Articles

Abstract ES9-3: ES9-3 (Neo)adjuvant systemic therapy of TNBC: How much is enough?

IA Mayer
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): ES9-3.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-ES9-3
Published: 15 February 2017
View article
Journal Articles

Abstract OT2-01-04: SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy

F Andre, B Kaufman, D Juric, EM Ciruelos, H Iwata, IA Mayer, HS Rugo, P Conte, S Liobl, G Rubovszky, K Inoue, H Tesch, Y-S Lu, L Ryvo, A-S Longin, D Mills, C Wilke, C Germa, M Campone
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): OT2-01-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-OT2-01-04
Published: 15 February 2017
View article
Journal Articles

Abstract P4-22-15: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results

A Bardia, JR Diamond, IA Mayer, SJ Isakoff, V Abramson, AN Starodub, J O'Shaughnessy, K Kalinsky, R Moroose, N Shah, D Juric, GI Shapiro, M Guarino, AJ Ocean, WA Messersmith, JD Berlin, WA Wegener, RM Sharkey, DM Goldenberg, LT Vahdat
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P4-22-15.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-P4-22-15
Published: 15 February 2017
View article
Journal Articles

Abstract P4-22-18: Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer

P Munster, R Ismail-Khan, L Garcia-Estevez, IA Mayer, C Becerra, E Hamilton, R De Boer, AM Wardley, S-A Im, L Teixeira, Y Wang, F Su, C Germa, S Hirawat, D Juric
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P4-22-18.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-P4-22-18
Published: 15 February 2017
View article
Journal Articles

Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)

IA Mayer, CL Arteaga, R Nanda, KD Miller, K Jhaveri, AM Brufsky, H Rugo, DA Yardley, LT Vahdat, S Sadeghi, MW Audeh, L Rolfe, J Litten, A Knox, M Raponi, C Tankersley, J Isaacson, K Wride, DE Morganstern, C Vogel, RM Connolly, WJ Gradishar, R Patel, L Pusztai, M Abu-Khalaf
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P6-11-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-P6-11-03
Published: 15 February 2017
View article